| |  Online-Ressource |
|---|
| Verfasst von: | Horstmann, Kristin Theres [VerfasserIn]  |
|---|
| | Boumendil, A. [VerfasserIn] |
|---|
| | Finke, J. [VerfasserIn] |
|---|
| | Finel, H. [VerfasserIn] |
|---|
| | Kanfer, E. [VerfasserIn] |
|---|
| | Milone, G. [VerfasserIn] |
|---|
| | Russell, N. [VerfasserIn] |
|---|
| | Bacigalupo, A. [VerfasserIn] |
|---|
| | Chalandon, Y. [VerfasserIn] |
|---|
| | Diez-Martin, J. L. [VerfasserIn] |
|---|
| | Ifrah, N. [VerfasserIn] |
|---|
| | Chacon, M. Jurado [VerfasserIn] |
|---|
| | Dreger, Peter [VerfasserIn] |
|---|
| Titel: | Second allo-SCT in patients with lymphoma relapse after a first allogeneic transplantation. A retrospective study of the EBMT Lymphoma Working Party |
|---|
| Verf.angabe: | K. Horstmann, A. Boumendil, J. Finke, H. Finel, E. Kanfer, G. Milone, N. Russell, A. Bacigalupo, Y. Chalandon, J.L. Diez-Martin, N. Ifrah, M. Jurado Chacon, P. Dreger |
|---|
| E-Jahr: | 2015 |
|---|
| Jahr: | 9 March 2015 |
|---|
| Umfang: | 5 S. |
|---|
| Fussnoten: | Gesehen am 14.09.2020 |
|---|
| Titel Quelle: | Enthalten in: Bone marrow transplantation |
|---|
| Ort Quelle: | London : Springer Nature, 1997 |
|---|
| Jahr Quelle: | 2015 |
|---|
| Band/Heft Quelle: | 50(2015), 6, Seite 790-794 |
|---|
| ISSN Quelle: | 1476-5365 |
|---|
| Abstract: | The aim of this registry-based retrospective study was to analyze the outcome of second allogeneic hematopoietic SCT (alloHSCT_2) performed in patients with lymphoma who had relapsed after a first allogeneic transplant (alloHSCT_1). Patients ⩾18 years who had received an alloHSCT_2 for lymphoma relapse between 2000 and 2011 were eligible. One hundred and forty patients were identified. The diagnosis was Hodgkin lymphoma (HL) in 31%, diffuse large B-cell lymphoma in 14%, T-cell lymphoma in 12%, indolent lymphoma in 19%, mantle cell lymphoma in 16% and other lymphomas in 8% of the patients. The median interval from alloHSCT_1 to alloHSCT_2 was 19 (range 4-116) months. Disease status at alloHSCT_2 was chemosensitive in 46%, refractory in 43% and unknown in 11% of the patients. Three-year PFS, OS, relapse incidence and nonrelapse mortality were 19%, 29%, 58% and 23%, respectively. PFS and OS were significantly affected by refractory disease at alloHSCT_2 and a short interval between alloHSCT_1 and alloHSCT_2. Long-term PFS was observed across all lymphoma subsets except for aggressive B-cell lymphoma. In conclusion, alloHSCT_2 is feasible and can result in long-term disease control in patients with lymphoma recurrence after alloHSCT_1, in particular if relapse occurs late and is chemosensitive. |
|---|
| DOI: | doi:10.1038/bmt.2015.12 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext ; Verlag: https://doi.org/10.1038/bmt.2015.12 |
|---|
| | Volltext: https://www.nature.com/articles/bmt201512 |
|---|
| | DOI: https://doi.org/10.1038/bmt.2015.12 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| K10plus-PPN: | 1731788460 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Second allo-SCT in patients with lymphoma relapse after a first allogeneic transplantation. A retrospective study of the EBMT Lymphoma Working Party / Horstmann, Kristin Theres [VerfasserIn]; 9 March 2015 (Online-Ressource)
